![]() |
GALT | Galectin Therapeutics Inc |
Pharmaceutical Preparations |
Book value per $ invested | $ -1.18 |
Leverage | 689.14% |
Market Cap | $ 87.2m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -46.8m |
Margin | 1011.96% |
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.